What were the main outcomes of Pfizer's Annual Shareholder Meeting on April 28, 2016?

The main outcomes were the election of all director nominees, the ratification of KPMG LLP as the independent auditor, and the approval of executive compensation on an advisory basis. Several shareholder proposals did not pass.

Were there any significant shareholder proposals that were approved?

No, based on the voting results presented, none of the shareholder proposals regarding lobbying activities, director election policies, the right to act by written consent, or certain taxable events received majority approval.

What does it mean that executive compensation was approved 'on an advisory basis'?

An advisory vote on executive compensation, often called a 'Say-on-Pay' vote, allows shareholders to express their opinion on the company's executive compensation policies and practices. While non-binding, it provides valuable feedback to the Board of Directors and compensation committee regarding shareholder sentiment on how executives are compensated.

What is the significance of the 'Broker non-votes' mentioned in the filing?

Broker non-votes occur when a broker holding shares in 'street name' (i.e., in the broker's name, not the beneficial owner's name) does not receive instructions from the beneficial owner on how to vote on a particular proposal. In many cases, brokers are allowed to vote on 'routine' matters (like ratification of auditors) but not on 'non-routine' matters (like director elections or executive compensation) without specific instructions. A high number of broker non-votes can indicate a significant portion of shares that were not actively directed by their beneficial owners for certain key votes.

PFE 8-K: Shareholder Matters

Summary

This 8-K filing by Pfizer Inc. (PFE) on May 2, 2016, reports the results of its Annual Meeting of Shareholders held on April 28, 2016. The key takeaway for investors is the overwhelming approval of the Board of Directors nominees and the ratification of KPMG LLP as the independent registered public accounting firm. Additionally, shareholders approved, on an advisory basis, the compensation of Named Executive Officers. The filing also details the outcomes of several shareholder proposals, most of which did not receive majority support, indicating continued management alignment with the company's strategic direction as perceived by a significant portion of its shareholder base.

Key Highlights

1All nominated directors were overwhelmingly elected to the Board of Directors.
2Shareholders ratified the appointment of KPMG LLP as Pfizer's independent registered public accounting firm for the fiscal year 2016.
3The compensation of the Company's Named Executive Officers was approved on an advisory basis.
4Shareholder proposals regarding lobbying activities, director election policies, the right to act by written consent, and certain taxable events were not approved by shareholders.
5The Annual Meeting of Shareholders took place on April 28, 2016.
6Broker non-votes were recorded for most director elections and executive compensation, highlighting a segment of shareholders who may not have directly voted on these specific matters or whose shares were held in 'street name'.

PFIZER INC 8-K Report, Shareholder Vote Results (May 2, 2016)

Summary

Key Highlights

Frequently Asked Questions